These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
85 related articles for article (PubMed ID: 10888331)
1. Natural and synthetic analogues of actinomycin D as Grb2-SH2 domain blockers. Kim HK; Nam JY; Han MY; Son KH; Choi JD; Kwon BM; Takusagawa HL; Huang Y; Takusagawa F Bioorg Med Chem Lett; 2000 Jul; 10(13):1455-7. PubMed ID: 10888331 [TBL] [Abstract][Full Text] [Related]
2. Actinomycin D as a novel SH2 domain ligand inhibits Shc/Grb2 interaction in B104-1-1 (neu*-transformed NIH3T3) and SAA (hEGFR-overexpressed NIH3T3) cells. Kim HK; Nam JY; Han MY; Lee EK; Choi JD; Bok SH; Kwon BM FEBS Lett; 1999 Jun; 453(1-2):174-8. PubMed ID: 10403397 [TBL] [Abstract][Full Text] [Related]
3. Actinomycin D, C2 and VII, inhibitors of Grb2-SHC interaction produced by Streptomyces. Nam JY; Kim HK; Son KH; Kim SU; Kwon BM; Han MY; Chung YJ; Bok SH Bioorg Med Chem Lett; 1998 Aug; 8(15):2001-2. PubMed ID: 9873474 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of Shc/Grb2 protein-protein interaction suppresses growth of B104-1-1 tumors xenografted in nude mice. Kim HK; Jeong MJ; Kong MY; Han MY; Son KH; Kim HM; Hong SH; Kwon BM Life Sci; 2005 Dec; 78(3):321-8. PubMed ID: 16146636 [TBL] [Abstract][Full Text] [Related]
5. CD16-mediated p21ras activation is associated with Shc and p36 tyrosine phosphorylation and their binding with Grb2 in human natural killer cells. Galandrini R; Palmieri G; Piccoli M; Frati L; Santoni A J Exp Med; 1996 Jan; 183(1):179-86. PubMed ID: 8551221 [TBL] [Abstract][Full Text] [Related]
6. Grb2 binding to the different isoforms of Ret tyrosine kinase. Alberti L; Borrello MG; Ghizzoni S; Torriti F; Rizzetti MG; Pierotti MA Oncogene; 1998 Sep; 17(9):1079-87. PubMed ID: 9764818 [TBL] [Abstract][Full Text] [Related]
7. Changes in structural dynamics of the Grb2 adaptor protein upon binding of phosphotyrosine ligand to its SH2 domain. de Mol NJ; Catalina MI; Fischer MJ; Broutin I; Maier CS; Heck AJ Biochim Biophys Acta; 2004 Jul; 1700(1):53-64. PubMed ID: 15210125 [TBL] [Abstract][Full Text] [Related]
8. A conserved amino-terminal Shc domain binds to phosphotyrosine motifs in activated receptors and phosphopeptides. van der Geer P; Wiley S; Lai VK; Olivier JP; Gish GD; Stephens R; Kaplan D; Shoelson S; Pawson T Curr Biol; 1995 Apr; 5(4):404-12. PubMed ID: 7542991 [TBL] [Abstract][Full Text] [Related]
9. Involvement of proline-rich tyrosine kinase 2 in platelet activation: tyrosine phosphorylation mostly dependent on alphaIIbbeta3 integrin and protein kinase C, translocation to the cytoskeleton and association with Shc through Grb2. Ohmori T; Yatomi Y; Asazuma N; Satoh K; Ozaki Y Biochem J; 2000 Apr; 347(Pt 2):561-9. PubMed ID: 10749687 [TBL] [Abstract][Full Text] [Related]
10. Coupling between p210bcr-abl and Shc and Grb2 adaptor proteins in hematopoietic cells permits growth factor receptor-independent link to ras activation pathway. Tauchi T; Boswell HS; Leibowitz D; Broxmeyer HE J Exp Med; 1994 Jan; 179(1):167-75. PubMed ID: 7505797 [TBL] [Abstract][Full Text] [Related]
11. Crystal structures of the SH2 domain of Grb2: highlight on the binding of a new high-affinity inhibitor. Nioche P; Liu WQ; Broutin I; Charbonnier F; Latreille MT; Vidal M; Roques B; Garbay C; Ducruix A J Mol Biol; 2002 Feb; 315(5):1167-77. PubMed ID: 11827484 [TBL] [Abstract][Full Text] [Related]
12. Role of the Src homology 2 (SH2) domain and C-terminus tyrosine phosphorylation sites of SH2-containing inositol phosphatase (SHIP) in the regulation of insulin-induced mitogenesis. Wada T; Sasaoka T; Ishiki M; Hori H; Haruta T; Ishihara H; Kobayashi M Endocrinology; 1999 Oct; 140(10):4585-94. PubMed ID: 10499514 [TBL] [Abstract][Full Text] [Related]
13. The critical role of c-Src and the Shc/Grb2/ERK2 signaling pathway in angiotensin II-dependent VSMC proliferation. Sayeski PP; Ali MS Exp Cell Res; 2003 Jul; 287(2):339-49. PubMed ID: 12837289 [TBL] [Abstract][Full Text] [Related]
15. A screening method of SH2 domain ligands and blockers using a solid phase binding. Koh WS; Yoon SY; Lee EK; Lee EK; Kwon BM; Kim JW; Han MY Cancer Lett; 1997 Nov; 120(1):1-7. PubMed ID: 9570379 [TBL] [Abstract][Full Text] [Related]
16. The Shc-related adaptor protein, Sck, forms a complex with the vascular-endothelial-growth-factor receptor KDR in transfected cells. Warner AJ; Lopez-Dee J; Knight EL; Feramisco JR; Prigent SA Biochem J; 2000 Apr; 347(Pt 2):501-9. PubMed ID: 10749680 [TBL] [Abstract][Full Text] [Related]
17. Potent inhibition of Grb2 SH2 domain binding by non-phosphate-containing ligands. Yao ZJ; King CR; Cao T; Kelley J; Milne GW; Voigt JH; Burke TR J Med Chem; 1999 Jan; 42(1):25-35. PubMed ID: 9888830 [TBL] [Abstract][Full Text] [Related]
18. Formation of Shc-Grb2 complexes is necessary to induce neoplastic transformation by overexpression of Shc proteins. Salcini AE; McGlade J; Pelicci G; Nicoletti I; Pawson T; Pelicci PG Oncogene; 1994 Oct; 9(10):2827-36. PubMed ID: 8084588 [TBL] [Abstract][Full Text] [Related]
19. Discrimination between phosphotyrosine-mediated signaling properties of conventional and neuronal Shc adapter molecules. Nakamura T; Komiya M; Gotoh N; Koizumi S; Shibuya M; Mori N Oncogene; 2002 Jan; 21(1):22-31. PubMed ID: 11791173 [TBL] [Abstract][Full Text] [Related]
20. Nonphosphorylated peptide ligands for the Grb2 Src homology 2 domain. Oligino L; Lung FD; Sastry L; Bigelow J; Cao T; Curran M; Burke TR; Wang S; Krag D; Roller PP; King CR J Biol Chem; 1997 Nov; 272(46):29046-52. PubMed ID: 9360978 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]